In the case of AD, the therapeutic approach leans towards enhancing TREM2 activity through agonistic antibodies, which could bolster DAM functions, aiding Aβ clearance and potentially alleviating neural dysfunction, as seen in Section 4.2. This evidence concerns the gene TREM2 and Alzheimer disease.